Verona Pharma (VRNA)

[TheFinalCD]

VRNA 6.60


in his twisted little mind, he caused the drop in price

[AdRock23]

Boiler you are talking to 10 people. Would not waste your energy.

[BoilerRoom]

Listen to me I will make you rich

[BoilerRoom]

Weeeeeeeeeeeeee

[BoilerRoom]

$VRNA company must be diluting shares folks don’t let them steal your money!

[BoilerRoom]

Not looking good here today as I’ve been saying. Uh Oooop

[BoilerRoom]

Told you this was going down. Listen to me I will make you rich!

[TheFinalCD]

not necessarily true, ive seen this happened enough to know that some stocks that have a super high Institutional Ownership, usually get manipulated, and VRNA is showing 60% that means they own 60% of the float, that means they are in control, that means they usually control the action and where the price is going

imo

[TheFinalCD]

6.95X7.00

[BoilerRoom]

Hehe

[BoilerRoom]

Nah this would kept moving up not back down. IMO

[dinogreeves]

Big Pharma will scoop them up for 500 million dollars before Phase 3 completes or pay a hefty premium after Phase 3 is completed. The Phase 2 results were exceptional, the only way they can sit at the bargaining table is way before the Phase 3 trials are well into the next month or so.

[dinogreeves]

Our Strategy
We are focused on developing our product candidate, ensifentrine, which we believe has the potential to become an important and novel treatment for chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other respiratory diseases, including asthma. We own the global commercialization rights to ensifentrine.
Rapidly advance nebulized ensifentrine into Phase 3 for COPD
Nebulized ensifentrine is expected to start Phase 3 clinical trials in 2020 as a maintenance treatment for moderate to severe COPD. Millions of COPD patients urgently need better treatments as they remain symptomatic despite maximum treatment with currently available therapies. In the US alone, total annual medical costs, indirect and direct, relating to COPD are projected to rise to about $50 billion in 2020. We believe ensifentrine will have an important role as an add-on therapy for dual/triple treated patients.
Develop formulations of ensifentrine for handheld inhalers
In addition to nebulized ensifentrine, we have developed dry powder inhaler (DPI) and pressurised metered dose inhaler (pMDI) formulations of ensifentrine for less severe patients. Initial results from Phase 2 trials for the maintenance treatment of COPD are promising. In the US, DPI and pMDI handheld inhalers are the most widely used option for medication in COPD, with an estimated 5.5 million people using them for COPD maintenance therapy. This market was valued at approximately $9 billion in 2018.
Seek strategic relationships
We may seek strategic collaborations with leading biopharmaceutical companies to develop and commercialize ensifentrine. These partnerships could provide significant funding to advance the development of ensifentrine while allowing us to benefit from the development and commercialization expertise of our collaborators.
Develop ensifentrine for cystic fibrosis and severe asthma
We may develop ensifentrine for the treatment of cystic fibrosis and severe asthma. CF is considered an orphan disease by both the US and European regulatory authorities. According to WHO estimates, 300 million people suffer from asthma and it is the most common chronic disease amongst children.
Pursue development of ensifentrine in additional territories
Initially, we are developing ensifentrine for the US and European markets. However, we may also develop ensifentrine for other markets such as China, which has more than 50 million COPD patients and is estimated to grow to 70 million in 2030.
Acquire or in-license product candidates for respiratory diseases
We are leveraging our expertise in respiratory diseases to in-license or acquire additional clinical-stage product candidates. We are seeking assets with the potential to become novel treatments for respiratory diseases with significant unmet medical needs.

[dinogreeves]

A quote from Warren Buffet. The same applies here, this is my piggy bank, I don't care, I know what I own, I own shares in a multi billion dollar company for just under 100 million market cap, that met all the primary endpoints for phase 2 for a condition called COPD. I bought this and I locked up my shares to triple digit dollars after phase 3 is released. Book it.

"Games are won by players who focus on the playing field, not those who are glued to the scoreboard."

[dinogreeves]

Milo this ticker doesn't need babysitting, they can say what they want, but the fact remains, price target by Wedbush was raised to $60.00, enough cash in the coffins that will last them till September 2020, many pipeline, with one data was released on Sunday, which met primary endpoints, with all the doses, they didn't even have to tweak it. Market cap should reach 500 million in the coming weeks. One licensing deal with China, all bets are off, this thing flies.

[dinogreeves]

LMAO at you.

https://www.analystratings.com/articles/wedbush-reaffirms-their-buy-rating-on-verona-pharma-vrna/

[dinogreeves]

Maybe he has yet to realize he is an id$ot. I know where I stand with my hefty position.

[Milo1]

I have to say, I am enjoying the short's posts. I wonder how foolish people can be sometimes, and I am constantly amazed.

[BoilerRoom]

.60

[Polebarn]

$60...lol

[Milo1]

https://drug-dev.com/copd-market-set-to-hit-14-1-billion-by-2025/

[Milo1]

There are times when I feel like I have to educate investors about a particular stock. VRNA is not an example of that. The information is out there. You can trade this, short it, buy and hold, I don't care, the stock is only going to make steady moves upwards at this point. $30M+ traded today, nobody is going to influence, or slow the progression upwards.

[Milo1]

I invite you to short VRNA, I really do. Lol

[Milo1]

Uh... you realize they just raised the price target to $60 right? I don't know why people advertise their ignorance.

[Polebarn]

Nada. After tomorrow you will never talk about it again lol.

[ClayTrader]

* * $VRNA Video Chart 01-13-2020 * *

Link to Video - click here to watch the technical chart video

[eur06]

What a post!!Moving up already.
I strongly believe that’ll be the case!

[dinogreeves]

Remember folks, VRNA IPO at the same time as CR*TX, KO*D and BT*AI all the rest except VNRA have gone for top dollar some are in billion market caps. The time will come for this, give it 2 weeks we will join all of them in the same way that happened to them. Market makers shook the tree just like they did with the rest of the other ones, the market makers didn't like in and out traders so they exhausted them, now with Wedbush analyst upgrade this will start moving up. CR*TX didn't even have analyst upgrade but yet it climbed and climbed. Patience will pay off big time here.

[dinogreeves]

Book it.

[BoilerRoom]

No it won’t

[dinogreeves]

The day is not over by a long shot and we still have this week, next week, following week and months of trading, again, I will say this, in two weeks top double digit dollars is written all over this. Read this people

people in the market in London vs in the USA are two totally different types of investors.

It has been shown and case pleaded by simply reviewing London’s market vs ours and how the stock reacts.
$VRNA had 4mil in movement vs $SPCE 6mil vs a low cost $DARE which had 51mil and didn’t move more than $.30 at market open today.
Mind blowing how idiotic some people are on a clinically proven phase test result vs a contract or even against $SPCE whivh has no real results and only fables with dates they hope to hit.

[dinogreeves]

Give it two weeks this will in top double digit dollars.

[dinogreeves]

Nothing less than 500 million market cap, nothing. This is one of those things that the buyout could come any day before they complete the Phase 3.

[Milo1]

Buyout offers are going to flow like rivers!

[dinogreeves]

There is only one way and that is way up North. Simple, Wedbush Analyst Upgrade raised price target to $60.00 after the data for the COPD. Enough cash to last them till September 2020, data met all primary endpoints for huge market.

[Milo1]

Entire VRNA traded today! Going up!

[dinogreeves]

Similar pattern as CR*TX, no different. The cash in the coffin is enough that will last them till September 2020, this was classic shake the tree for big boys to load.

[Milo1]

Looks the we are going to have a nice ride up over the coming weeks!

[dinogreeves]

Funds are taking positions, thus huge market maker favors, the same set pattern the same as CR*TX, this will be double digit dollars in no time.

[Milo1]

Can you be any more ridiculous?

[dinogreeves]

Wedbush price target raised to $60.00 after COPD results.

[BoilerRoom]

Bullchit no such rating

[dinogreeves]

https://www.streetinsider.com/Analyst+PT+Change/Verona+Pharma+%28VRNA%29+PT+Raised+to+Street+High+%2460+at+Wedbush/16328420.html

[TheFinalCD]

please post analysts PT upgrade

[BoilerRoom]

What ride???

[TheFinalCD]

Uptimber, you mad because you didnt buy sub 7 like some of us

and also because you didnt short it @ 9.80

[Milo1]

The door was just opened for the institutional investors! Perfect time of the year as well. This float is going to get locked up quick!

[BoilerRoom]

Timber

[kairos]

In for the ride ... VRNA

[TheFinalCD]

sorry to repost, I needed the laugh from that poor soul





BoilerRoom Member Level Monday, 01/13/20 12:52:24 PM
Re: dinogreeves post# 86 0
Post #
87
of 87



Listen to the better trader.... I will make you a rich man